Publications scientifiques

Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.

Auteurs : Falchero, L ; Guisier, F ; Darrason, M ; Boyer, A ; Dayen, C ; Cousin, S & al.

Revue : Lung Cancer

Année : 2023

Groupe : QuantIF

Evaluation of sarcopenia biomarkers in older patients undergoing major surgery for digestive cancer.

Auteurs : Gagnat G, Hobeika C, Modzelewski R, Collet CS, Di Fiore F, Druesne L, Tuech JJ, Schwarz L.

Revue : Eur J Surg Oncol

Année : 2023

Groupe : QuantIF

Preoperative Radiation Therapy for Chemorefractory Localized Inflammatory Breast Cancer.

Auteurs : Rogé M, Kirova Y, Loap P, Amar S, Servagi S, Nebbache R, Rivin Del Campo E, Clatot F, Thureau S, Thariat J.

Revue : Pract Radiat Oncol.

Année : 2023

Groupe : QuantIF

Guidelines for the management of male urinary tract infections in primary care: a lack of international consensus-a systematic review of the literature.

Auteurs : Soudais B, Ribeaucoup F, Schuers M.

Revue : Family Practice

Année : 2023

Groupe : RecSaN

A literature survey of MR-based brain tumor segmentation with missing Modalities

Auteurs : Zhou T, Ruan S, Hu H.

Revue : Comput Med Imaging Graph

Année : 2023

Groupe : QuantIF

Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ?50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study).

Auteurs : Decroisette, C ; Greillier, L ; Curcio, H ; Pérol, M ; Ricordel, C ; Auliac, JB & al (Guisier F).

Revue : J Immunother

Année : 2023

Groupe : QuantIF

[Thoracic calcifications].

Auteurs : Allera H, Cohu M, Maley K, Crabot D, Karila-Cohen P, Strauss C, Lidove O, Cotto E.

Revue : Rev Med Interne

Année : 2023

Groupe : SML

Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial.

Auteurs : Wasserstein MP, Lachmann R, Hollak C, Barbato A, Gallagher RC, Giugliani R, Guelbert NB, Hennermann JB, Ikezoe T, Lidove O, Mabe P, Mengel E, Scarpa M, Senates E, Tchan M, Villarrubia J, Thurberg BL, Yarramaneni A, Armstrong NM, Kim Y, Kumar M.

Revue : Orphanet J Rare Dis.

Année : 2023

Groupe : SML

Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 study.

Auteurs : Gendarme, S ; Zebachi, S ; Corre, R ; Greillier, L ; Justeau, G ; Bylicki, O & al (Guisier F).

Revue : J Geriatr Oncol, 2023

Année : 2023

Groupe : QuantIF

Impact of EGFRA289T/V mutation on relapse pattern in glioblastoma.

Auteurs : Noeuveglise A, Sarafan-Vasseur N, Beaussire L, Marguet F, Modzelewski R, Hanzen C, Alexandru C, Magne N, Langlois O, Di Fiore F, Clatot F, Thureau S, Fontanilles M.

Revue : ESMO Open

Année : 2023

Groupe : QuantIF

Evaluation of the capability and reproducibility of RECIST 1.1. measurements by technologists in breast cancer follow-up: a pilot study.

Auteurs : Gouel P, Callonnec F, Levêque É, Valet C, Blôt A, Cuvelier C, Saï S, Saunier L, Pepin LF, Hapdey S, Libraire J, Vera P, Viard B.

Revue : Sci Rep.

Année : 2023

Groupe : QuantIF

Video abstracts are associated with an increase in research reports citations, views and social attention: a cross-sectional study.

Auteurs : Bonnevie T, Repel A, Gravier FE, Ladner J, Sibert L, Muir JF, Cuvelier A, Fischer MO.

Revue : Scientometrics

Année : 2023

Groupe : RecSaN

1 … 4 5 6 7 8 … 39